Vaxart, Inc. filings document a clinical-stage biotechnology issuer focused on oral recombinant pill vaccines and a common stock quoted on the OTCQX Best Market under the symbol VXRT. The company’s regulatory record includes financial-result 8-K reports, registration statements and registration-rights disclosures tied to common stock financing, and exhibits covering material agreements.
The filings also cover board appointments and independence determinations, lease terminations and facility changes, capital structure items, revenue categories such as government contract and collaboration revenue, and formal market-status records, including a Form 25 for removal of the common stock from Nasdaq listing and registration.
Vaxart, Inc. director Raquel C. Bono reported a restricted-stock-unit award covering 78,800 common shares and a stock-option award for 157,400 common shares on October 16, 2026. Both awards vest in equal installments on each of the first three anniversaries of the grant date, subject to her continuing service on the Board. The options have a $0.4527 exercise price and expire October 16, 2036.
Vaxart, Inc. appointed Raquel C. Bono, M.D., to its board effective immediately on October 16, 2026; the board determined she meets its independence standards. She will chair the Stockholder Engagement Committee and serve on the Nominating and Governance Committee and the Clinical and Regulatory Affairs Committee.
Vaxart said the appointment was pursuant to a cooperation agreement entered into with a group of its stockholders in July 2026. Dr. Bono previously led a $50 billion integrated global healthcare system serving 9.5 million beneficiaries as Director of the Defense Health Agency.
Vaxart, Inc. (VXRT) reported that its Board of Directors approved two governance policies on September 3, 2026. A new Director Resignation Policy requires any director who receives more "withhold" votes than "for" votes in an uncontested election to promptly tender a written resignation after certification of the stockholder vote. The Nominating and Governance Committee must review the offer and recommend whether to accept or reject it, and the Board must act on that recommendation within 90 days of vote certification.
The Board also adopted a Director Stock Ownership Policy, setting a target ownership level for non-employee directors equal to two times the current annual cash retainer for Board service, excluding committee or other incremental fees. Compliance will be measured annually as of December 31 using a 90-day simple moving average of the Company’s common stock price, and includes directly and indirectly owned shares as well as service-based restricted stock and restricted stock units.
Vaxart, Inc. (VXRT) reports that its Board of Directors has created two new committees: a Clinical and Regulatory Affairs Committee and a Stockholder Engagement Committee. The new Clinical and Regulatory Affairs Committee will review and provide oversight and advice on Vaxart’s research, clinical, and regulatory programs on behalf of the Board, and consists of James B. Breitmeyer, M.D., Ph.D. (Chair) and David Wheadon, M.D.. The Stockholder Engagement Committee will oversee the advancement of the company’s relations with stockholders, and consists of W. Mark Watson (Interim Chair) and Steven Lo. Under a Cooperation Agreement dated July 1, 2026, Vaxart anticipates appointing a new director in the future to serve as Chair of the Stockholder Engagement Committee. Vaxart notes that its common stock is quoted on the OTCQX Best Market under the symbol VXRT and includes a standard forward-looking statements disclaimer regarding the anticipated new director appointment.
Vaxart, Inc. reported Q2 2026 revenue of $27.2 million, including $24.3 million from HHS BARDA contracts and $2.9 million from its Dynavax/Sanofi collaboration. For the first half of 2026, revenue was $66.4 million, compared with $60.6 million a year earlier.
Research and development expenses declined year over year, and six‑month net loss was $8.3 million versus $30.6 million in 2025, with slightly positive operating cash flow of $0.7 million. Cash, cash equivalents and short‑term investments totaled $64.0 million as of June 30, 2026.
Management states these resources are not sufficient to fund planned operations for 12 months and raises substantial doubt about continuing as a going concern, even though current plans project runway into the second quarter of 2027. BARDA’s Phase 2b COVID‑19 ATI‑RRPV contract was amended, reducing authorized funding from $460.7 million to $344.8 million. Capital access tools include an unused $50 million at‑the‑market program and a $25.0 million equity line with Lincoln Park, under which only $44,000 has been drawn. Previously disclosed securities litigation has been resolved through a 2022 settlement and a 2026 jury verdict in favor of a co‑defendant, with an opt‑out case dismissed.
Vaxart, Inc. reported its business update and financial results for the quarter ended June 30, 2026. The company released topline data from a 400-person sentinel cohort in its Phase 2b COVID-19 trial, showing safety of its oral pill vaccine compared with an approved mRNA comparator. Topline efficacy and safety data from the approximately 5,000-participant main cohort are anticipated in the first half of 2027.
For the second quarter of 2026, Vaxart reported revenue of $27.2 million, compared with $39.7 million a year earlier, and a net loss of $13.5 million. Revenue for the first six months of 2026 was $66.4 million. Cash, cash equivalents and investments totaled $64.0 million as of June 30, 2026, giving the company a stated cash runway into the second quarter of 2027.
Vaxart plans a live stockholder fireside chat on August 7, 2026 at 4:30 p.m. ET, accessible via webcast in the investor section of its website, to address frequently asked stockholder questions and discuss these updates.
Vaxart, Inc., a Delaware corporation whose common stock is quoted on the OTCQX Best Market under the symbol VXRT, reported changes to the structure of its Board committees.
On July 27, 2026, the Board approved a reorganization of the Nominating and Governance Committee and the Compensation Committee, effective August 1, 2026. Kevin P. Finney was appointed chair of the Nominating and Governance Committee, which will also include David Wheadon, M.D. The Compensation Committee will be chaired by James B. Breitmeyer, M.D., Ph.D., with Elaine J. Heron, Ph.D. and W. Mark Watson serving as members.
Vaxart director Kevin Finney reported equity awards dated July 16, 2026. He received 39,400 shares of Common Stock upon vesting of restricted stock units, bringing his direct holdings to 244,171 shares. He was also granted 78,700 stock options with a $0.5149 exercise price, expiring July 16, 2036. Both the RSU shares and options vest on the earlier of the date immediately prior to Vaxart’s 2027 annual meeting of stockholders and July 16, 2027, the first anniversary of the grant.
Vaxart, Inc. director James B. Breitmeyer reported equity awards dated July 16, 2026. He acquired 8,315 shares of common stock in connection with restricted stock units that will vest on the earlier of the date immediately prior to the 2027 annual stockholder meeting and July 16, 2027, bringing his direct holdings to 87,115 shares. He was also granted options on 16,610 shares at an exercise price of $0.5149 per share, expiring July 16, 2036, with the options subject to the same vesting schedule.